The role of PPARγ in pulmonary vascular disease

被引：12
作者：
Hart, C. Michael [1 ,2 ]
机构：
[1] Atlanta Vet Affairs, Atlanta, GA USA
[2] Emory Univ, Med Ctr, Atlanta, GA 30322 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2008年 / 56卷 / 02期
关键词：
PPAR gamma; pulmonary hypertension; nitric oxide; NADPH oxidase;
D O I：
10.2310/JIM.0b013e318165e921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The peroxisome proliferator-activated receptor (PPAR) gamma is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Thiazolidine-diones, pharmacological ligands for PPAR gamma, are currently used in the management of type 2 diabetes. Peroxisome proliferator-activated receptor gamma is expressed in the lung and pulmonary vasculature, and its expression is reduced in the vascular lesions of patients with pulmonary hypertension. Furthermore, thiazolidinedione PPAR gamma ligands reduced pulmonary hypertension and vascular remodeling in several experimental models of pulmonary hypertension. This report reviews current evidence that PPAR gamma may represent a novel therapeutic target in pulmonary hypertension and examines studies that have begun to elucidate mechanisms that underlie these potential terapeutic effects.
引用
收藏
页码：518 / 521
页数：4
相关论文
共 24 条
[1]   Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth [J].
Ameshima, S ;
Golpon, H ;
Cool, CD ;
Chan, D ;
Vandivier, RW ;
Gardai, SJ ;
Wick, M ;
Nemenoff, RA ;
Geraci, MW ;
Voelkel, NF .
CIRCULATION RESEARCH, 2003, 92 (10) :1162-1169
[2]   Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells [J].
Calnek, DS ;
Mazzella, L ;
Roser, S ;
Roman, J ;
Hart, CM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) :52-57
[3]   Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors [J].
Campia, U ;
Matuskey, LA ;
Panza, JA .
CIRCULATION, 2006, 113 (06) :867-875
[4]  
Chen SY, 2001, SPECTROSC SPECT ANAL, V21, P377
[5]   Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice [J].
Collins, AR ;
Meehan, WP ;
Kintscher, U ;
Jackson, S ;
Wakino, S ;
Noh, G ;
Palinski, W ;
Hsueh, WA ;
Law, RE .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :365-371
[6]   Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration, in NIDDM patients [J].
Cominacini, L ;
Garbin, U ;
Fratta Pasini, A ;
Campagnola, M ;
Davoli, A ;
Foot, E ;
Sighieri, G ;
Sironi, AM ;
Lo Cascio, V ;
Ferrannini, E .
DIABETES, 1998, 47 (01) :130-133
[7]   Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling [J].
Crossno, Joseph T. ;
Garat, Chrystelle V. ;
Reusch, Jane E. B. ;
Morris, Kenneth G. ;
Dempsey, Edward C. ;
McMurtry, Ivan F. ;
Stenmark, Kurt R. ;
Klemm, Dwight J. .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2007, 292 (04) :L885-L897
[8]   INTERACTION OF THE PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR AND RETINOID X-RECEPTOR [J].
GEARING, KL ;
GOTTLICHER, M ;
TEBOUL, M ;
WIDMARK, E ;
GUSTAFSSON, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (04) :1440-1444
[9]   Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation [J].
Hansmann, Georg ;
Wagner, Roger A. ;
Schellong, Stefan ;
Perez, Vinicio A. de Jesus ;
Urashima, Takashi ;
Wang, Lingli ;
Sheikh, Ahmad Y. ;
Suen, Renee S. ;
Stewart, Duncan J. ;
Rabinovitch, Marlene .
CIRCULATION, 2007, 115 (10) :1275-1284
[10]   The PPARγ ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice [J].
Hwang, Jinah ;
Kleinhenz, Dean J. ;
Rupnow, Heidi L. ;
Campbell, Adam G. ;
Thule, Peter M. ;
Sutliff, Roy L. ;
Hart, C. Michael .
VASCULAR PHARMACOLOGY, 2007, 46 (06) :456-462
123